Loading clinical trials...
Loading clinical trials...
The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China
Conditions
Locations
9
China
Baogang Hospital
Baotou, Inner Mongolia, China
Baotou Cancer Hospital
Baotou, Inner Mongolia, China
Northern Hospital Baotou
Baotou, Inner Mongolia, China
Baotou Centry Hospital
Baotou, Inner Mongolia, China
Bayan Nur Hospital
Bayan Nur, Inner Mongolia, China
The Inner Mongolia Autonomous Region Cancer Hospital
Hohhot, Inner Mongolia, China
Start Date
November 1, 2016
Primary Completion Date
October 1, 2018
Completion Date
December 1, 2018
Last Updated
July 11, 2018
NCT05039801
NCT05691465
NCT05692635
NCT05198830
NCT04704661
NCT06696768
Lead Sponsor
Berry Genomics Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions